Article
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.
Cancer immunology, immunotherapy : CII - 1 Jan 2020
Ozaki Yuki, Muto Satoshi, Takagi Hironori, Watanabe Masayuki, Inoue Takuya, Fukuhara Mitsuro, Yamaura Takumi, Okabe Naoyuki, Matsumura Yuki, Hasegawa Takeo, Ohsugi Jun, Hoshino Mika, Shio Yutaka, Tanaka Daisuke, Nanamiya Hideaki, Imai Jun-Ichi, Isogai Takao, Watanabe Shinya, Suzuki Hiroyuki
Abstract excerpt
Cancer treatment using immune checkpoint inhibitors is widely used, although biomarkers predictive of response are not well established. However, both the expressions of programmed cell death ligand 1 (PD-L1) and the tumor mutation burden (TMB) hold promise as such biomarkers for immune checkpoint inhibitors; however, its characteristics and clinical and immunological impacts have not been fully analyzed. We,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.